Showing 15 posts of 79 posts found.

GSK image

EU submission for GSK and Theravance COPD drug

January 11, 2013
Sales and Marketing COPD, GSK, Theravance, UMEC/VI

GlaxoSmithKline and Theravance have submitted their chronic obstructive pulmonary disease (COPD) drug UMEC/VI to European regulators. The application follows the …

Eisai image

Eisai and Novartis part ways

January 8, 2013
Sales and Marketing COPD, Eisai, Novartis, Onbrez, Spiriva

Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows …

Seebri Breezhaler approved in Europe

October 4, 2012
Sales and Marketing COPD, Novartis, Relvar, Seebri Breezhaler, Tudorza

Novartis has been given approval in Europe for its Seebri Breezhaler to be used as maintenance treatment for chronic obstructive …


Novartis cheered by COPD trial results

September 3, 2012
Research and Development COPD, ERS, Novartis

One of Novartis’ experimental respiratory drugs has proved superior in a late-stage trial to Boehringer Ingelheim and Pfizer’s existing brand …

Boehringer posts strong financials

August 16, 2012
Sales and Marketing AMNOG, Boehringer, COPD, Spiriva

Boehringer Ingelheim has seen steady growth in the first half of 2012, but warns that the next six months may …

Forest labs image

FDA approves Forest’s COPD drug

July 25, 2012
Sales and Marketing COPD, FDA, Forest, Tudorza Pressair

US regulators have approved Forest Laboratories’ new chronic obstructive pulmonary disease (COPD) drug. Tudorza Pressair (aclidinium bromide) has been given …

GSK image

GSK and Theravance post COPD pill data

July 2, 2012
Research and Development, Sales and Marketing COPD, GSK, LABA, LAMA, Theravance

GSK and partner Theravance have released new data for its combination COPD drug. Results from four late-stage trials suggest that …

PMCPA reprimands Chiesi for multiple breaches

June 18, 2012
Sales and Marketing COPD, Chiesi, GSK, PMCPA, code

Chiesi has been publicly reprimanded by the PMCPA part for promoting its asthma drug Fostair off-label. The embarrassing slapdown from …


Boehringer seeks NHS partners for COPD campaign

June 1, 2012
Medical Communications, Sales and Marketing Boehringer, COPD, disease awareness campaign

Boehringer is seeking NHS partners for its COPD campaign: ‘Know it. Check it. Treat it.’  The campaign aims to raise …

Boehringer’s COPD drug passes hurdle

May 23, 2012
Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol

Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial.  The manufacturer wants the …

GSK buys more of Theravance

May 18, 2012
Research and Development, Sales and Marketing COPD, Cellzome, GSK, Relovair, Theravance

GlaxoSmithKline now owns more than a quarter of biopharma company Theravance after shelling out nearly $213 million to buy ten …

abpi image

ABPI launches new NHS partnership guide

May 15, 2012
Medical Communications, Sales and Marketing ABPI, COPD, NHS, code

The Association of the British Pharmaceutical Industry has launched a new guide to explain how pharma and the NHS can …

FDA picture

Prescription drugs could become OTC under FDA plans

March 12, 2012
Sales and Marketing COPD, FDA, OTC, prescribing

The FDA is considering new plans to make drugs for chronic conditions available over-the-counter. These drugs could include medicines for …

Underwhelming results for GSK’s Relovair

January 10, 2012
Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma

GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …


NICE rejects Merck’s COPD drug Daxas

December 9, 2011
Sales and Marketing COPD, Daxas, Merck, Nycomed

NICE has not recommended Merck’s COPD drug Daxas and is asking for a new clinical trial to test its effectiveness. …

Latest content